Evidence map›Paper›PMID 35418279›Full record

ArticleEmerging microbes & infections2022

N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19)

Michaela Lackner, Annika Rössler, André Volland, Marlena Nastassja Stadtmüller, Brigitte Müllauer, Zoltan Banki, Johannes Ströhle, Angela Luttick, Jennifer Fenner, Bettina Sarg and 7 more

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. International journal of molecular sciences · 2024
    Article
  4. Activity ofInternational journal of molecular sciences · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Metabolites · 2022
    Article
  10. Recombinant actin-depolymerizing factor of the apicomplexanFrontiers in cellular and infection microbiology · 2022
    Article
  11. Review
  12. Activity ofAntibiotics (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 4 countries.

Michaela LacknerInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-9073-2886
Annika RösslerInstitute of Virology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-5298-0288
André VollandInstitute of Virology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0003-2805-8215
Marlena Nastassja StadtmüllerUnit 17-Influenza and Other Respiratory Viruses, Robert Koch-Institute, Berlin, Germany.ORCID 0000-0001-8893-5326
Brigitte MüllauerInstitute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Zoltan BankiInstitute of Virology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-3826-5800
Johannes StröhleInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Angela Luttick360biolabs Pty Ltd, Melbourne, Australia.
Jennifer Fenner360biolabs Pty Ltd, Melbourne, Australia.
Bettina SargInstitute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-4785-8739
Leopold KremserInnovative Biomedical Concepts, Inc., Staten Island, NY, USA.
Paul ToneInnovative Biomedical Concepts, Inc., Staten Island, NY, USA.
Heribert StoiberInstitute of Virology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-4266-8397
Dorothee von LaerInstitute of Virology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-5825-7237
Thorsten WolffUnit 17-Influenza and Other Respiratory Viruses, Robert Koch-Institute, Berlin, Germany.ORCID 0000-0001-7688-236X
Carsten SchwarzCF Center Westbrandenburg, Division Cystic Fibrosis, Pediatric Clinic Westbrandenburg, Potsdam, Germany.ORCID 0000-0002-1461-4439
Markus NaglInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-1225-9349
Innsbruck Medical University · ATRobert Koch Institute · DECystic Fibrosis Research Foundation · ITEnergy Concepts (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentRespiratory Tract InfectionsHumansInfluenza A Virus, H3N2 SubtypeRespiratory Syncytial VirusesSARS-CoV-2Spike Glycoprotein, CoronavirusTaurineN-chlorotaurineSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Taurineanti-infectiveantisepticantiviralCOVID-19influenzaN-chlorotaurinerespiratory syncytial virusrespiratory tract

Identifiers

PMID35418279
PMCPMC9132425
OpenAlexW4223992719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.